Abstract:Backgrounds: Epidermal growth factor receptor (EGFR) mutation profiles play a vital role in treatment strategy decisions for non–small cell lung cancer (NSCLC). The purpose of this study was to evaluate the predictive efficacy of baseline 18 F-FDG PET/CT-based radiomics analysis for EGFR mutation status, mutation site, and the survival benefit of targeted therapy. Methods: A sum of 313 NSCLC patients with pre-treatment 18 F-FDG PET/CT scans and genetic mutations detection were retrospectively studied. Clinical and PET metabolic parameters were incorporated into independent predictors of determining mutation status and mutation site. The dataset was randomly allocated into the training and the validation sets in a 7:3 ratio. Three-dimensional (3D) radiomics features were extracted from each PET- and CT-volume of interests (VOI) singularly, and then a radiomics signature (RS) associated with EGFR mutation profiles is built by feature selection. Three different prediction models based on support vector machine (SVM), decision tree (DT), and random forest (RF) classifiers were established. Furthermore, nomograms for estimation of overall survival (OS) and progression-free survival (PFS) were established by integrating PET/CT radiomics score (Rad-score), metabolic parameters, and clinical factors. Predictive performance was assessed by the receiver operating characteristic (ROC) analysis and the calibration curve analysis. The decision curve analysis (DCA) was applied to estimate and compare the clinical usefulness of nomograms. Results: Three hundred thirteen NSCLC patients were classified into a training set (n=218) and a validation set (n=95). Multivariate analysis demonstrated that SUVmax and sex were independent indicators of EGFR mutation status and mutation site. Eight CT-derived RS, six PET-derived RS, and two clinical factors were retained to develop integrated models, which exhibited excellent ability to distinguish between EGFR wild type (EGFR-WT), EGFR 19 mutation type (EGFR-19-MT), and EGFR 21 mutation type (EGFR-21-MT). The SVM model outperformed the RF model and the DT model, yielding training area under the curves (AUC) of EGFR-WT, EGFR-19-WT, and EGFR-21-WT, with 0.881, 0.851, and 0.849, respectively, and validation AUCs of 0.926, 0.805 and 0.859, respectively. For prediction of OS, the integrated nomogram is superior to the clinical nomogram and the radiomics nomogram, with C-indexes of 0.80 in the training set and 0.83 in the validation set, respectively. Conclusions: The PET/CT-based radiomics analysis might provide a novel approach to predict EGFR mutation status and mutation site in NSCLC patients and could serve as useful predictors for the patients' survival outcome of targeted therapy in clinical practice.

18F-RGD PET/CT and Systemic Inflammatory Biomarkers Predict Outcomes of Patients With Advanced NSCLC Receiving Combined Antiangiogenic Treatment

The Predictive Value of 18F-FDG PET/CT Combined with Inflammatory Index for Major Pathological Reactions in Resectable NSCLC Receiving Neoadjuvant Immunochemotherapy.

18 F-RGD PET/CT imaging reveals characteristics of angiogenesis in non-small cell lung cancer.

A Novel Analytical Approach for Outcome Prediction in Newly Diagnosed NSCLC Based on [ 18 F]FDG PET/CT Metabolic Parameters, Inflammatory Markers, and Clinical Variables

Predictive Value of Early Responses with 18F-Alfatide RGD PET in Locally Advanced Non-Small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy

The role of 18F-FDG PET/CT in predicting the pathological response to neoadjuvant PD-1 blockade in combination with chemotherapy for resectable esophageal squamous cell carcinoma

Utility of 18 F-FDG uptake in predicting major pathological response to neoadjuvant immunotherapy in patients with resectable non‐small cell lung cancer

Radiolabelled anti-PD-L1 peptide PET/CT in predicting the efficacy of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer

Utility of 18F-FDG Uptake in Predicting Major Pathological Response to Neoadjuvant Immunotherapy in Patients with Resectable Non‑small Cell Lung Cancer.

Dynamic 18F-FDG Total body PET Imaging as a predictive marker of induction chemo-immunotherapy response in locally advanced non-small cell lung cancer.

Utility of 18F-FDG PET/CT Uptake Values in Predicting Response to Neoadjuvant Chemoimmunotherapy in Resectable Non-Small Cell Lung Cancer.

PET/CT Radiomic Features: A Potential Biomarker for EGFR Mutation Status and Survival Outcome Prediction in NSCLC Patients Treated With TKIs

Negative Correlation Between 18F-RGD Uptake via PET and Tumoral PD-L1 Expression in Non-Small Cell Lung Cancer

The utility of 18F-FDG PET/CT for predicting the pathological response and prognosis to neoadjuvant immunochemotherapy in resectable non-small-cell lung cancer

Comprehensive 18F-FDG PET-based Radiomics in Elevating the Pathological Response to Neoadjuvant Immunochemotherapy for Resectable Stage III Non-Small-cell Lung Cancer: A Pilot Study

The Clinical Pathologic Characteristics Of Angiogenesis Obtained By 18f-Rgd Pet In Patients With Non-Small Cell Lung Cancer

The Predictive Value of Serial 18F-FDG PET/CT for Recurrence and Survival of Locally Advanced Non-Small Cell Lung Cancer after Concurrent Chemoradiation Therapy

Tumor metabolic and secondary lymphoid organ metabolic markers on 18F-fludeoxyglucose positron emission tomography predict prognosis of immune checkpoint inhibitors in advanced lung cancer

Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non‐small cell lung cancer patients with neoadjuvant immunotherapy

18 F-FDG PET/CT for Evaluation of Metastases in Nonsmall Cell Lung Cancer on the Efficacy of Immunotherapy.